Erste Asset Management GmbH Purchases 14,819 Shares of Eli Lilly and Company $LLY

Key Points

• Erste Asset Management GmbH increased its holdings in Eli Lilly and Company by 51.5%, purchasing an additional 14,819 shares during the first quarter, bringing its total shares to 43,617 valued at approximately $35.9 million.
• Eli Lilly reported earnings of $6.31 per share for the most recent quarter, significantly exceeding analyst expectations of $5.59, and showed a 37.6% year-over-year revenue growth.
$1.50 per share, with an ex-dividend date on August 15th, representing a 0.9% annual yield.

Erste Asset Management GmbH increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 51.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,617 shares of the company's stock after buying an additional 14,819 shares during the quarter. Erste Asset Management GmbH's holdings in Eli Lilly and Company were worth $35,876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Knightsbridge Asset Management LLC increased its stake in Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the period. Corient IA LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $570,000. LS Investment Advisors LLC increased its stake in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. Prism Advisors Inc. purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $207,000. Finally, CSM Advisors LLC increased its stake in Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.8%

LLY stock opened at $703.5670 on Wednesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The business's 50-day moving average is $760.97 and its two-hundred day moving average is $793.02. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $665.90 billion, a price-to-earnings ratio of 45.98, a P/E/G ratio of 0.97 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Insider Buying and Selling

In other news, Director Jamere Jackson bought 200 shares of the stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday. Finally, Leerink Partners reissued a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.